Merck (MRK) as a reliable dividend for dogs in the Dow Lineup

Merck & Co., Inc. (NYSE:mrk) is included in Buy Now 11 Dow Dividend Stock Dogs.

Close-up of a person’s hand holding a medicine bottle.

Merck & Co., Inc. (NYSE:MRK) faces stock pressure due to its reliance on Keytruda, but it is diversifying. On July 9, Merck announced it would acquire UK biotech Verona Pharma for $10 billion, adding Ohtuvayre, a promising COPD treatment approved last year, to its portfolio. Ohtuvayre has a strong launch and is being studied for more applications. Some analysts predict that its revenue could reach $4 billion, potentially making it another blockbuster for Merck.

With first quarter revenue, Merck & Co., Inc. (NYSE: MRK) highlighted that it started with strong advances in the year, leading to increased contributions from recently commercialized drugs and vaccines, and ongoing advances in the pipeline. We are determined to focus and take full advantage of short-term opportunities while rapidly moving forward with the next wave of innovation that will improve patient outcomes and create long-term value for all stakeholders.

Merck & Co., Inc. (NYSE:MRK) has also become popular due to its dividend growth history for the 16th consecutive year. Currently, the company offers a quarterly dividend of $0.81 per share, and as of July 26th, it has a dividend yield of 3.82%.

Although we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater promotion opportunities and pose a risk of decline. If you’re looking for a highly undervalued AI stock that can make a significant profit from the tariff and supervision trends of the Trump era, check out our free report. Best Short-Term AI Stocks.

Read next: Top 10 Safe Dividend Stocks in the UK and Dividend Champions and Nobles: 12 Under the Radar Stocks to Buy

Disclosure: None.